{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-093144","form_type":"8-K","ticker":"NVCT","cik":"0001875558","company_name":"Nuvectis Pharma, Inc.","filed_at":"2025-09-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.478520+00:00","generated_at":"2026-05-17T05:42:18.842512+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Nuvectis Pharma appoints biotech executive Juan Sanchez, MD to Board of Directors","bullets":["Juan Sanchez, MD appointed to board effective Sept 22, 2025; term expires at 2026 annual meeting.","Sanchez served as VP of Corp Comm & IR at Intra-Cellular Therapies, acquired by J&J for $14.6B in April 2025.","He brings 30+ years experience in biotech, capital markets, and clinical medicine.","Company plans to start Phase 1b program for NXP900, a precision oncology drug candidate.","No arrangements or family relationships; no material transactions per Item 404(a)."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-093144","json":"https://secwatch.observer/filing/0001104659-25-093144.json","markdown":"https://secwatch.observer/filing/0001104659-25-093144.md","text":"https://secwatch.observer/filing/0001104659-25-093144.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925093144/0001104659-25-093144-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1875558/000110465925093144/tm2526892d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:42:18.842512+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}